| Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity GK Griffin, J Wu, A Iracheta-Vellve, JC Patti, J Hsu, T Davis, D Dele-Oni, ... Nature 595 (7866), 309-314, 2021 | 218 | 2021 |
| In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma J Dubrot, SK Lane-Reticker, EA Kessler, A Ayer, G Mishra, CH Wolfe, ... Immunity 54 (3), 571-585. e6, 2021 | 62 | 2021 |
| Targeting TBK1 to overcome resistance to cancer immunotherapy Y Sun, O Revach, S Anderson, EA Kessler, CH Wolfe, A Jenney, CE Mills, ... Nature 615 (7950), 158-167, 2023 | 38 | 2023 |
| The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity CK Baumgartner, H Ebrahimi-Nik, A Iracheta-Vellve, KM Hamel, ... Nature 622 (7984), 850-862, 2023 | 32 | 2023 |
| An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers E Przybytkowski, T Davis, A Hosny, J Eismann, UA Matulonis, GM Wulf, ... BMC cancer 20, 1-16, 2020 | 27 | 2020 |
| Targeting the immune checkpoint PTPN2 with ABBV-CLS-484 inflames the tumor microenvironment and unleashes potent CD8+ T cell immunity A Iracheta-Vellve, H Ebrahimi-Nik, TR Davis, KE Olander, SY Kim, ... Cancer Research 82 (12_Supplement), 606-606, 2022 | 4 | 2022 |
| Abstract A41: Small molecule inhibition of PTPN2/1 inflames the tumour microenvironment and unleashes potent CD8+ T cell immunity H Ebrahimi-Nik, A Iracheta-Vellve, KE Olander, TRG Davis, SY Kim, ... Cancer Immunology Research 10 (12_Supplement), A41-A41, 2022 | | 2022 |
| Abstract PO009: Epigenetic silencing by SETDB1 represses tumor-cell intrinsic immunogenicity J Wu, A Iracheta-Vellve, J Patti, J Hsu, T Davis, D Dele-Oni, P Du, ... Cancer Immunology Research 9 (2_Supplement), PO009-PO009, 2021 | | 2021 |
